US Patent

US11672938 — Start-up protocols for nitric oxide delivery device

Method of Use · Assigned to Vero Biotech Inc · Expires 2040-07-22 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects start-up protocols for a device used to administer nitric oxide.

USPTO Abstract

Start-up protocols for a device and method for administering NO is described.

Drugs covered by this patent

Inomax (NITRIC OXIDE) · Vero Biotech Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3037`	—	Inomax

Patent Metadata

Patent number: US11672938
Jurisdiction: US
Classification: Method of Use
Expires: 2040-07-22
Drug substance claim: No
Drug product claim: No
Assignee: Vero Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.